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This study aimed to compare the effects of volatile anesthesia and total intravenous anesthesia (TIVA) 
on syndecan‑1 shedding in patients with gastric cancer undergoing minimally invasive gastrectomy. 
Patients were randomly assigned to either the Volatile (n = 68) or the TIVA (n = 68) group. Anesthesia 
was maintained with sevoflurane/remifentanil or propofol/remifentanil in the Volatile and TIVA 
groups, respectively. Serum syndecan‑1 was evaluated at pre‑operation, end of operation, and 
postoperative day (POD) 1. Inflammatory markers including white blood cell (WBC) count, neutrophil‑
to‑lymphocyte ratio (NLR), and C‑reactive protein (CRP), were also measured at pre‑operation, end 
of operation, and POD 1, 2, 3, and 5. The TIVA group showed significantly lower levels of syndecan‑1 
at the end of the operation compared to the Volatile group; however, no difference was seen between 
the groups at POD 1. The WBC count and NLR were significantly lower in the TIVA group at the end 
of the operation than the Volatile group, but there were no differences between the groups at POD 1, 
2, 3, and 5. CRP levels were similar between the groups at all time points. In conclusion, despite TIVA 
being superior to volatile anesthesia in protecting endothelial glycocalyx during the operation, both 
did not prevent postoperative syndecan‑1 shedding after gastrectomy.
Clinical trial registration number: NCT04183296 (ClinicalTrial.gov, 03/12/2019).
The endothelial glycocalyx (EG) is a gel-like layer that coats the luminal surface of the vascular endothelium, with 
thicknesses between 0.2 and 2 μm depending on the type of  vasculature1–3. The EG is degraded under pathological 
conditions, such as ischemia–reperfusion (I/R) injury, oxidative stress, and  inflammation1–3. Proteoglycans are 
the most important backbone molecule of the EG, and heparan sulfate proteoglycans represent about 50–90% 
of the  proteoglycans1,2. Syndecans are a family of heparan sulfate proteoglycan, and syndecan-1 has been widely 
studied as a marker of EG breakdown in various conditions, including in surgical  patients4–13.
Since no pharmacologic agents for the restoration of the EG are clinically available, strategies to prevent 
EG degradation in surgical patients are  needed3. There have been experimental studies on the protective effect 
of sevoflurane against EG degradation from I/R  injury14–16. Sevoflurane was superior to propofol in protecting 
the EG from I/R injury in a porcine  model16. In contrast to experimental results, sevoflurane did not show a 
better protective effect on the EG than propofol in clinical studies of lung resection surgery and knee-ligament 
 surgery9,10.
Minimally invasive laparoscopic surgery causes less surgical trauma compared to open surgery, which leads 
to less stress and attenuated inflammatory  response17,18. In minimally invasive abdominal surgery, pneumop-
eritoneum is essential for adequate visualization and working space. However, abdomen insufflation causes a 
reduction in splanchnic blood flow, which causes organ ischemia followed by reperfusion injury upon deflation 
of the abdomen, resulting in oxidative  stress19. Although I/R injury and oxidative stress are highly related to EG 
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disruption, no study has evaluated the perioperative EG changes in minimally invasive abdominal surgery with 
pneumoperitoneum, nor the effect of different general anesthetics on these changes. Hence, this randomized 
controlled trial aimed to compare the effect of volatile anesthesia with sevoflurane/remifentanil and of total 
intravenous anesthesia (TIVA) with propofol/remifentanil on syndecan-1 shedding in patients with gastric 
cancer undergoing laparoscopic or robotic gastrectomy.
Results
Demographic and intraoperative characteristics. Of the 139 patients assessed for eligibility, 136 
patients were randomly assigned into the two groups, and 132 of those patients completed the study (97%). Four 
patients were excluded from the final analysis (three patients from the Volatile group and one from the TIVA 
group) because of open and closure or conversion to open surgery (Fig. 1). The patients’ characteristics and intra-
operative variables are shown in Table 1. The administered dose of remifentanil was significantly higher in the 
TIVA group (P < 0.001), whereas significantly higher doses of ephedrine and phenylephrine were administered 
to the Volatile group (both P < 0.001). No differences were observed between the two groups in other variables. 
Intraoperative MAP was significantly higher in the TIVA group at 30, 60, and 90 min after pneumoperitoneum 
compared to the Volatile group (Bonferroni corrected P = 0.012, 0.016, and 0.034, respectively; Fig. 2A). No sta-
tistical differences in heart rate were found between the two groups (Fig. 2B). Arterial partial pressures of oxygen 
and carbon dioxide at 90 min after pneumoperitoneum showed no significant differences between the Volatile 
and TIVA groups (202 ± 31 vs 206 ± 31 mmHg, P = 0.642 and 39 ± 4 vs 39 ± 3 mmHg, P = 0.977, respectively).
Syndecan‑1. The serum concentration of syndecan-1 was significantly increased at the end of the operation 
compared to preoperative values, and this increase was maintained until POD 1 in the Volatile group. However, 
in the TIVA group, syndecan-1 was significantly elevated at POD 1 but not at the end of the operation. There-
fore, the TIVA group showed significantly lower levels of syndecan-1 at the end of the operation compared to 
the Volatile group (23.4 ± 11.7 vs 29.3 ± 14.7 ng/mL; Bonferroni corrected P = 0.021), but no difference existed 
between the groups at POD 1 (29.1 ± 13.1 ng/mL in the Volatile group vs 28.0 ± 12.9 ng/mL in the TIVA group; 
Fig. 3). Even after adjusting for confounding variables (MAP, dose of ephedrine, and dose of phenylephrine) 
which may contribute to organ ischemia, the syndecan-1 level was significantly lower in the TIVA group at the 
end of the operation compared to the Volatile group (Bonferroni corrected P = 0.042, data not shown), while 
there was no difference between the groups at POD1. When compared to preoperative values, 19 patients (44%) 
in the Volatile group and 24 patients (56%) in the TIVA group presented an elevation of syndecan-1 of more than 
30% at POD 1 (P = 0.149, data not shown).
Figure 1.  Consort flow diagram of the study.
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Table 1.  Patients’ characteristics and intra-operative variables Values are presented as mean ± SD or number of 
patients (percentage). TIVA: total intravenous anesthesia; ASA: American Society of Anesthesiologists; TNM: 
tumor-node-metastasis.
Variable Volatile group (n = 65) TIVA group (n = 67) P value
Age (year) 64.6 ± 10.4 61.5 ± 9.0 0.068
Male sex 37 (57%) 29 (43%) 0.117
Body mass index (kg/m2) 23.2 ± 2.9 24.0 ± 2.8 0.108
ASA physical status 0.688
I/II/III 9 (14%)/39 (60%)/17 (26%) 8 (12%)/45 (67%)/14 (21%)
Co-morbidities
Hypertension 27 (42%) 18 (27%) 0.075
Diabetes mellitus 13 (20%) 8 (12%) 0.206
Type of operation 0.834
Robotic/Laparoscopic 26 (40%)/39 (60%) 28 (42%)/39 (58%)
Type of gastrectomy 0.420
Subtotal/Total/Proximal subtotal 51 (79%)/12 (18%)/2 (3%) 58 (87%)/7 (10%)/2 (3%)
Type of reconstruction 0.091
Billoth I 36 (55%) 40 (60%)
Billoth II 8 (12%) 15 (22%)
Double tract 3 (5%) 4 (6%)
Roux-en-Y 18 (28%) 8 (12%)
Extent of lymph node dissection 0.383
D1/D2 43 (66%)/22 (34%) 49 (73%)/18 (27%)
TNM stage 0.788
I/II/III/IV 41 (63%)/14 (21%)/7 (11%)/3 (5%) 47 (70%)/12 (18%)/4 (6%)/4 (6%)
Intra-operative variables
Pneumoperitoneum time (min) 151 ± 42 149 ± 47 0.769
Operation time (min) 183 ± 43 182 ± 49 0.923
Anesthesia time (min) 214 ± 44 213 ± 48 0.938
Crystalloid intake (mL) 1254 ± 413 1331 ± 436 0.300
Colloid intake (mL) 368 ± 284 321 ± 253 0.319
Blood loss (mL) 69 ± 65 68 ± 90 0.936
Urine output (mL) 191 ± 98 181 ± 112 0.590
Remifentanil dose (μg) 940 ± 330 1294 ± 464  < 0.001
Ephedrine dose (mg) 6.8 ± 5.7 3.4 ± 4.9  < 0.001
Phenylephrine dose (μg) 1522 ± 2026 411 ± 1008  < 0.001
Figure 2.  Intraoperative changes in (A) mean arterial pressure (MAP) and (B) heart rate (HR). Pneumo, 
pneumoperitoneum; OP, operation; TIVA, total intravenous anesthesia. Values are expressed as mean ± SD. 
*Bonferroni-corrected P < 0.05 versus Volatile group.
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WBC count, NLR, and CRP. The WBC count and NLR were significantly lower in the TIVA group at the 
end of the operation than in the Volatile group (Bonferroni corrected P = 0.049 and 0.013, respectively), while no 
differences were found between the groups at POD 1, 2, 3, and 5 (Fig. 4A,B). In addition, there was no difference 
in the CRP levels between the groups at any time point (Fig. 4C).
Postoperative consumption of analgesics and hospital stay. The cumulative doses of fentanyl at 
postoperative 6, 12, and 24 h were similar in both groups (Fig. 5A). Likewise, no significant differences were 
observed in the number of patients who required rescue analgesics between the two groups (Fig. 5B). The post-
operative hospital stay was of 6.5 ± 3.5 days in the Volatile group and 6.0 ± 2.2 days in the TIVA (P = 0.352).
Discussion
This randomized controlled study was the first to explore the perioperative changes of syndecan-1 and the effects 
of two commonly used general anesthetics on these changes in minimally invasive abdominal surgery with 
pneumoperitoneum. Our study showed that the serum concentration of syndecan-1 was significantly increased 
at POD 1 compared to preoperative levels, and that the increase was comparable between patients under volatile 
anesthesia with sevoflurane/remifentanil and those under TIVA with propofol/remifentanil. Our results further 
confirmed previous findings indicating that sevoflurane and propofol have similar effects regarding periopera-
tive EG  degradation9,10.
The EG layer is a fine structure that lines the endoluminal surface of the endothelium and acts as a regulator 
of endothelial  function1–3. It is a labile structure and can be easily destroyed by a variety of enzymes and reac-
tive oxygen species under inflammatory  conditions1–3. Acute degradation of the EG has been demonstrated 
in patients after cardiac surgery, sepsis, and major trauma, and elevation of EG markers in blood is associ-
ated with poor outcomes in these  patients3,6,8. Although previous studies have shown EG shedding in patients 
after major abdominal  surgery5,7, literature on EG degradation after minimally invasive abdominal surgery was 
scarce. Minimally invasive abdominal surgery implies less inflammatory response compared to open surgical 
 techniques17,18, from which it could be inferred that minimally invasive abdominal surgery would cause less EG 
damage. However, on the other hand, pneumoperitoneum applied in minimally invasive surgeries is known to 
induce I/R injury with reactive oxygen species  formation19, which is another source of EG damage in addition 
to inflammatory response. Ultimately, our study revealed that there is a significant EG degradation in patients 
after minimally invasive laparoscopic or robotic gastrectomy.
The EG is composed of proteoglycans, glycoproteins, glycosaminoglycans, and associated plasma proteins, 
including  albumin1,2. Proteoglycans consist of a core membrane-bound protein, such as those of the syndecan 
family, to which glycosaminoglycan side chains are  attached1,2. Among glycosaminoglycans, heparan sulfate is 
the most prominent  glycosaminoglycan1. Therefore, syndecan-1 (core protein) and heparan sulfate (glycosami-
noglycan) have been the most commonly used markers of EG damage in medical and surgical  patients4–13. The 
core protein syndecan-1 strongly binds to the cell membrane via a membrane-spanning domain, whereas heparan 
sulfate is a side chain attached to  it1,2. Therefore, heparan sulfate is shed first and syndecan-1 is shed later, when 
severe EG damage  occurs1,3. In cardiac surgery with cardiopulmonary bypass (CPB), syndecan-1 blood levels 
elevated following the elevation of heparan sulfate; syndecan-1 levels remained elevated until POD 3, whereas 
heparan sulfate levels were restored to baseline after weaning from  CPB13. Therefore, syndecan-1 may be a better 
marker to detect severe injury and more stable than heparan sulfate.
There was approximately a 20% increase in serum syndecan-1 at POD 1 compared to preoperative values in 
our patients. This increase is lower than previously reported increases of syndecan-1 of 40–70% at 24 h follow-
ing major abdominal  surgery5,7. The discrepancy may arise from the difference in the extent of surgical trauma 
and the duration of the operation because (1) we studied only minimally invasive surgery, whereas previous 
studies included open surgery mostly, and (2) we included only gastrectomy, whereas previous studies included 
various types of abdominal  surgery5,7. In fact, different types of surgery have been associated with perioperative 
variations in serum syndecan-1 levels; increases of 30–40% have been reported after lung resection  surgery9,11, 
whereas up to 65-fold increases have been reported after major vascular surgery with  CPB4.
Figure 3.  Perioperative changes in serum syndecan-1. OP, operation; POD, postoperative day; TIVA, total 
intravenous anesthesia. Values are expressed as mean ± SD. *Bonferroni-corrected P < 0.05 versus Volatile group. 
†Bonferroni-corrected P < 0.05 versus Pre-OP in each group.
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After acute degradation of the EG, 5–7 days are required to endogenously restore the EG thickness in  mice20. 
There are no clinically available pharmacologic agents for EG restoration; hence, efforts to minimize EG degra-
dation may be  important3. Strategies to minimize EG damage include avoiding hypervolemia, supplementing 
with albumin, and administering pharmacologic agents (e.g., glucocorticoids, antioxidants, and antithrombin 
III)2,3,12,21. Volatile anesthetics were also considered as one of the candidates for EG protection because of their 
protective effects against I/R  injury14–16. Sevoflurane has been proven to reduce EG shedding caused by I/R injury 
through attenuation of the post-ischemic release of lysosomal protease cathepsin  B14, and through the inhibition 
of post-ischemic leukocyte and platelet  adhesion15. Moreover, sevoflurane significantly reduced heparan sulfate 
shedding after I/R injury compared to propofol by reducing the generation of unmeasured  anions16. However, 
contradictory to the reported protective effects of sevoflurane on EG damage in animal  models14–16, sevoflurane 
was not superior to propofol in reducing EG degradation in surgical  patients9,10. In lung resection surgery with 
one lung ventilation, no difference was observed in heparan sulfate and syndecan-1 concentrations between 
sevoflurane and propofol groups during  surgery9. Likewise, no difference existed in heparan sulfate and synde-
can-1 concentrations between the two groups up to 90 min after tourniquet release in knee-ligament  surgery10. 
Figure 4.  Perioperative changes in (A) white blood cell (WBC) counts, (B) neutrophil/lymphocyte ratio (NLR), 
and (C) C-reactive protein (CRP). OP, operation; POD, postoperative day; TIVA, total intravenous anesthesia. 
Values are expressed as mean ± SD. *Bonferroni-corrected P < 0.05 versus Volatile group.
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These two studies presented design differences compared to our study: sevoflurane or propofol alone was used 
for general anesthesia maintenance without concomitant use of  opioids9, and sevoflurane or propofol was used 
for hypnosis under spinal  anesthesia10. On the contrary, we administered remifentanil in addition to sevoflurane 
or propofol because opioids are frequently used during general anesthesia with hypnotic agents. Hence, our 
study may reflect common clinical settings, and in these conditions we showed no superior effects of volatile 
anesthesia with sevoflurane/remifentanil over TIVA with propofol/remifentanil on perioperative EG damage.
Although there was no difference in syndecan-1 levels at POD 1 between the groups, the TIVA group showed 
significantly lower levels of syndecan-1 at the end of the operation compared to the Volatile group (Bonferroni 
corrected P = 0.021). This result is comparable to the significantly lower WBC count and NLR in the TIVA group 
at the end of the operation compared to the Volatile group (Bonferroni corrected P = 0.049 and 0.013, respec-
tively). The NLR is the ratio of neutrophil count to lymphocyte count and is considered as a more sensitive marker 
of systemic inflammation than the measures of either cell type  alone22. Therefore, lower levels of WBC count 
and NLR may reflect an attenuated inflammatory response in the TIVA group, which could have prevented EG 
degradation during the surgery. However, since sevoflurane also has anti-inflammatory  properties23 and since 
CRP levels were similar between the groups, further studies are needed to draw definitive conclusions. Moreo-
ver, the protective effects of TIVA against EG damage were only limited to the surgery and were not maintained 
in the postoperative period. Hence, volatile anesthesia and TIVA can be considered comparable regarding EG 
protection in minimally invasive abdominal surgery.
This study has some limitations. First, the sample size was not calculated beforehand due to the lack of 
previous reports. However, the number of patients in our study is larger than that of previous clinical studies 
comparing syndecan-1 between two treatment  groups7,9,10,12,21. Second, we evaluated syndecan-1 only until POD 
1 based on previous  studies7,12. However, we evaluated WBC count, NLR, and CRP levels until POD 5 and no 
differences were found between the groups. Therefore, there may be no difference in syndecan-1 levels between 
the groups after POD 1 either. Moreover, syndecan-1 returned to baseline levels 48 h after abdominal  surgery5; 
thus, evaluation after POD 1 may be meaningless.
In conclusion, EG damage was observed following minimally invasive laparoscopic or robotic gastrectomy 
with approximately 20% postoperative increase in serum syndecan-1. Although TIVA with propofol/remifentanil 
showed protective effects against EG damage during the surgery in contrast to volatile anesthesia with sevoflu-
rane/remifentanil, both types of anesthetics could not prevent postoperative syndecan-1 shedding. These results 
argue against a favorable effect of volatile anesthetics over TIVA on perioperative EG damage in experimental 
studies, whereas support the previous clinical studies demonstrating comparable effects of these agents on EG 
damage in surgical patients.
Methods
Patients. This study was approved by the Institutional Review Board (IRB) and Hospital Research Ethics 
Committee (Yonsei University Health System, Seoul, Korea; IRB protocol No. 4-2019-0924) and was registered 
at http://clini caltr ials.gov (ClinicalTrial.gov, NCT04183296, 03/12/2019). This study was performed in accord-
ance with relevant guidelines and regulations. After obtaining written informed consent from each patient, 
a total of 136 patients with gastric cancer who were waiting for a laparoscopic or robotic gastrectomy were 
enrolled between November 2019 and July 2020. Patients were excluded if they fulfilled any of the following 
criteria: emergency operation; severe hepatic dysfunction (alanine aminotransferase > 3 times of upper normal 
limit) or end-stage renal disease; allergy or hypersensitivity to sevoflurane or propofol; neurological or psychiat-
ric impairment; history of thromboembolism; and treatment with oral contraceptives or anticoagulants.
Study design. Patients were randomly assigned to either the Volatile (n = 68) or the TIVA (n = 68) group 
with the permuted block size of four. In the Volatile group, a bolus of propofol (1.5–2 mg/kg) and target-con-
trolled infusion (TCI) of remifentanil (effect-site concentration [Ce] of 4.0 ng/ml) were administered for anes-
thetic induction. In the TIVA group, anesthetic induction was achieved by TCI of propofol (Ce of 4.0–4.5 μg/
mL) and remifentanil (Ce of 4.0 ng/ml). A commercial TIVA pump (Orchestra Base Primea, Fresenius-Vial, 
Sèvres, France) was used for TCI of remifentanil and propofol. For anesthesia maintenance, age-adjusted mini-
mal alveolar concentration end-tidal sevoflurane of 0.8–1.0 and TCI of remifentanil were used in the Volatile 
Figure 5.  (A) Cumulative fentanyl dose administered via intravenous patient-controlled analgesia, and (B) 
use of rescue analgesics during the first 24 h after operation. TIVA, total intravenous anesthesia. Values are 
expressed as mean ± SD or percentage.
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group, while TCI of propofol and remifentanil were used in the TIVA group to target a Patient State Index (PSI) 
within the range of 25–50.
Anesthetic management. Upon arrival at the operating room, all required monitoring devices, including 
electrocardiography, non-invasive blood pressure, peripheral oxygen saturation, PSI using a SedLine electro-
encephalograph sensor (Masimo Corp., Irvine, CA), and peripheral nerve stimulator, were applied. After the 
administration 0.1 mg of intravenous glycopyrrolate as a premedication, anesthetic induction was performed as 
abovementioned. After loss of consciousness, 1.2 mg/kg of rocuronium was administered to facilitate tracheal 
intubation, and the degree of neuromuscular blockade was maintained, with 0–2 train-of-four as a target, by 
rocuronium infusion during pneumoperitoneum. Controlled ventilation was performed at a tidal volume of 
7–8 mL/kg with 50% oxygen in air to maintain end-tidal carbon dioxide  (CO2) at 35–40 mmHg, and a posi-
tive end-expiratory pressure of 5 cm  H2O was applied. Radial artery cannulation was performed in all patients. 
Hypotension (mean arterial pressure [MAP] < 60 mmHg) was controlled with ephedrine in 4-mg increments or 
with phenylephrine in 20-μg increments. A forced-air warming system was applied to maintain body tempera-
ture at 36–37 °C. Pneumoperitoneum was induced by  CO2 insufflation, and the intra-abdominal pressure was 
maintained at 12 mmHg. At the beginning of umbilical closure, 1 μg/kg of fentanyl and 0.3 mg of ramosetron 
were administered for the prevention of postoperative pain and nausea and vomiting, respectively. All patients 
were provided with an IV patient-controlled analgesia (PCA) device (Accumate 1100; WooYoung Medical, 
Seoul, Korea), which consisted of fentanyl infused basally at a rate of 8 µg/h with a bolus dose of 8 µg and a 
lockout time of 10 min. At the end of the operation, residual neuromuscular blockade was reversed with sugam-
madex 2 mg/kg intravenously.
Data collection. Hemodynamic variables (MAP and heart rate) were measured at the following operation 
time points: before induction, at 30, 60, and 90 min of  CO2 pneumoperitoneum, and at the end of the opera-
tion and arterial blood gas analysis was performed at 90 min of  CO2 pneumoperitoneum. The primary outcome 
was serum syndecan-1, which was evaluated at 3 time points: pre-operation (baseline), at the end of the opera-
tion, and at postoperative day (POD) 1. Extracted blood samples were centrifuged at 5000 rpm for 5 min at 
4 °C to obtain serum and were stored in a -80 °C freezer until analyzed. The analysis was performed by using a 
specific immunoassay kit (Abnova,Cat. No. KA3851,Taiwan) and all samples were tested in duplicate. In addi-
tion, the inflammatory markers, white blood cell (WBC) count, neutrophil-to-lymphocyte ratio (NLR), and 
C-reactive protein (CRP) were measured at pre-operation, at the end of the operation, and at POD 1, 2, 3, and 
5. Postoperatively administered doses of fentanyl at postoperative 6, 12, and 24 h were registered using the PCA 
device, which automatically recorded the delivered quantities of drug every 30 min. The number of patients who 
required rescue analgesics (25 mg of intravenous pethidine) was also registered up to postoperative 24 h.
Statistical analysis. The primary outcome was perioperative syndecan-1, which was compared between 
volatile anesthesia and TIVA groups. Previous studies on perioperative changes of syndecan-1 concentration 
after abdominal surgery with pneumoperitoneum were not found; thus, this study was designed with 68 patients 
per group. This number is higher than that of previous studies on the effect of sevoflurane and propofol on 
perioperative syndecan-1  shedding9,10.
Continuous variables are shown as mean ± SD and categorical variables are expressed as number of patients 
(percentage). Group differences for continuous variables were analyzed by the Student’s t test, which is valid 
according to the central limit theorem because of the large number of patients (65 and 67). Differences in cat-
egorical variables were checked by the Chi-square test or by the Fisher’s exact test: the former was employed if 
the portion of cells with an expected cell frequency of less than 5 was less than 20% of all the cells, and the latter 
was employed otherwise. For repeated-measure variables, a linear mixed model analysis was employed to deter-
mine group and time effects and a compound symmetry covariance structure was used for the within-subject 
effect. The Bonferroni correction was used to adjust for multiple comparison in post-hoc analyses. A P value of 
less than 0.05 was considered to be significant. All analyses were conducted using SAS version 9.4 (Cary, NC).
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